


13TH ANNUAL
STATE OF THE HEART
ONDEMAND VIRTUAL WEBCAST
 Recorded Live on:
May 25, June 1, June 8, 2022
PLANNING COMMITTEE


Jacques Genest,
 MD, CM, FRCPC, FACC, FAHA
CO-CHAIR
 Professor of Medicine,
 McGill University
 McGill/Novartis Chair in Medicine,
 McGill University Health Centre/
 Royal Victoria Hospital,
 Montreal, QC



Milan Gupta,
 MD, FRCPC, FCCS, FACC, FAHA
CO-CHAIR
 Associate Clinical Professor
 McMaster University
 Medical Director, Canadian
 Collaborative Research Network
 Brampton, ON



Ajay Kapur,
 MD, FRCPC
 St Josephs Health Centre Toronto
 GIM at St Josephs Health Centre
 Toronto, ON



Laura Reardon,
 MD, CCFP, ABOM Diplomate
 Medical Director, Lotus Health Clinic
 Diplomate, American Board of
 Obesity Medicine
 Halifax, NS



Kevin Saunders,
 MD CCFP
 Medical Director,
 The Wellness Institute,
 Seven Oaks General Hospital
 University of Manitoba
 Winnipeg, MB



Sol Stern,
 B.Sc., M.Sc., MD, MCFP
 Lead, Family Physician, Argus Medical
 Centre Family Health Organization
 Co-Medical Director, Sea Courses/
 CME Away
 Ajax, ON

AGENDA
SESSION 1
LEARNING OBJECTIVES

- Explore current role of GLP-1 agonists in clinical practice
- Recognize the impact of kidney protection for cardiac protection
- Determine when to use medical vs surgical treatment in stable CAD
- Describe appropriate antiplatelet therapy for stable CAD patients

Opening Comments

GLP-1 agonists: underused and underappreciated?

CKD: save the kidneys, save the heart

Stable CAD: when to use antianginals and when to revascularize

Stable CAD: ASA alone, prolonged DAPT or low-dose rivaroxaban?

Discussion and Q+A

Program Close

 Darren McGuire
 David Cherney
 Tara Sedlak
 Marc Sabatine
 All Faculty

SESSION 2
LEARNING OBJECTIVES

- Describe a guideline centric approach to manage and support patients with obesity
- Distinguish the appropriate use of ezetimibe or PCSK9 inhibitors in secondary prevention
- Discuss the role of a new market entrance in lipid management
- Apply guideline centric strategies for managing cardiovascular risk beyond LDL-C

Opening Comments

Have we entered a new era in obesity management?

When to use ezetimibe or PCSK9 inhibitors in secondary prevention

Inclisiran: the new LDL kid on the block

Cardiovascular risk reduction: more than just LDL-C

Discussion and Q+A

Program Close

 Megha Poddar
 Jacques Genest
 Milan Gupta
 Deepak Bhatt
 All Faculty

SESSION 3
LEARNING OBJECTIVES

- Summarize the benefits and challenges with using DOAC's
- Describe appropriate management strategies and therapies for managing patients with HFrEF and HFpEF
- Explore developments in cardiovascular medicine that may change how we treat patients in the future

Opening Comments

Lessons learned after a decade of experience with DOAC's

HFrEF: how to start and titrate the four pillars of treatment

HFpEF: which drugs have become standard of care?

CV medicine in the next decade: predicting the future

Discussion and Q+A

Program Close

 Paul Dorian
 Nadia Giannetti
 Milan Gupta
 Deepak Bhatt
 All Faculty

 Watch the recording on
 MD-Online here:

www.md-online.com

> MDWatch

This program received unrestricted educational funding from Bayer, BMS/Pfizer Alliance, Boehringer Ingelheim, Janssen, KYE Pharmaceuticals, and Sanofi